Bai Ruoli, Hamel Ernest
Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, MD 21702, USA.
Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, MD 21702, USA.
Arch Biochem Biophys. 2016 Aug 15;604:63-73. doi: 10.1016/j.abb.2016.06.008. Epub 2016 Jun 13.
The most potent microtubule assembly inhibitor of newer diphenylpyridazinone derivatives examined was NSC 613241. Because NSC 613241 and (-)-rhazinilam also induce the formation of similar 2-filament spirals, these aberrant reactions were compared. Spiral formation with both compounds was enhanced by GTP and inhibited by GDP and by 15 other inhibitors of microtubule assembly. Similarly, microtubule assembly induced by paclitaxel or laulimalide is enhanced by GTP and inhibited by GDP and assembly inhibitors, but neither [(3)H]NSC 613241 nor (3)H-rhazinilam bound to microtubules or inhibited the binding of [(3)H]paclitaxel or [(3)H]peloruside A to microtubules. Differences in the pitch of aberrant polymers were found: NSC 613241-induced and (-)-rhazinilam-induced spirals had average repeats of 85 and 79-80 nm, respectively. We found no binding of [(3)H]NSC 613241 or (3)H-rhazinilam to αβ-tubulin dimer, but both compounds were incorporated into the polymers they induced in substoichiometric reactions, with as little as 0.1-0.2 mol compound/mol of tubulin, and no cross-inhibition by NSC 613241 or (-)-rhazinilam into spirals occurred. Under reaction conditions where neither compound induced spiral formation, both compounds together synergistically induced substantial spiral formation. We conclude that (-)-rhazinilam and NSC 613241 bind to different sites on tubulin that differ from binding sites for other antitubulin agents.
在所研究的新型二苯基哒嗪酮衍生物中,活性最强的微管组装抑制剂是NSC 613241。由于NSC 613241和(-)-rhazinilam也会诱导形成相似的双丝螺旋,因此对这些异常反应进行了比较。两种化合物形成螺旋均受到GTP增强,受到GDP和其他15种微管组装抑制剂抑制。同样,紫杉醇或劳利马胺诱导的微管组装也受到GTP增强,受到GDP和组装抑制剂抑制,但[(3)H]NSC 613241和(3)H-rhazinilam均不与微管结合,也不抑制[(3)H]紫杉醇或[(3)H]peloruside A与微管的结合。发现异常聚合物的螺距存在差异:NSC 613241诱导的螺旋和(-)-rhazinilam诱导的螺旋平均重复距离分别为85和79 - 80纳米。我们发现[(3)H]NSC 613241或(3)H-rhazinilam不与αβ-微管蛋白二聚体结合,但在亚化学计量反应中,两种化合物都被整合到它们诱导形成的聚合物中,每摩尔微管蛋白只需0.1 - 0.2摩尔化合物,并且NSC 613241或(-)-rhazinilam不会交叉抑制螺旋形成。在两种化合物均未诱导螺旋形成的反应条件下,二者共同作用可协同诱导大量螺旋形成。我们得出结论,(-)-rhazinilam和NSC 613241与微管蛋白上的不同位点结合,这些位点不同于其他抗微管蛋白药物的结合位点。